Modulating the Cell Death Immune Response for Electroporation Treatments.

Irreversible electroporation (IRE) is a minimally invasive ablation technique that compromises integrity of the cell membrane through the application of short duration, high voltage electric pulses to induce cell death. Adverse effects of IRE such as muscle contractions are reduced with higher frequency biphasic pulsing, commonly known as high-frequency irreversible electroporation (H-FIRE). IRE and H-FIRE treatments have shown to increase immune activation through the induction of both immediate and delayed cell death, indicated by the release of damage-associated molecular pathways, antigens, and proteins.

Global patterns of species diversity and distribution in the biomedically and biotechnologically important fungal genus .

fungi are key producers of pharmaceuticals, enzymes, and food products and exhibit diverse lifestyles, ranging from saprophytes to opportunistic pathogens. To improve understanding of species diversity, identify key environmental factors influencing their geographic distributions, and estimate the impact of future climate change, we trained a random forest machine learning classifier on 30,542 terrestrial occurrence records for 176 species (~40% of known species in the genus) and 96 environmental variables. We found that regions with high species diversity are concentrated in temperate forests, which suggests that areas with mild seasonal variation may serve as diversity hotspots.

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.

Purpose: We conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with classical Hodgkin lymphoma (cHL; ClinicalTrials.gov identifier: NCT03033914).

Methods: Patients age ≥60 years with newly diagnosed, any stage, cHL were treated with six cycles of AVD at standard doses plus nivolumab 240 mg intravenously once every 2 weeks (on days 1 and 15) of each cycle.

No longer to be ignored: Hypophosphatemia following intravenous iron administration.

Intravenous iron supplementation is increasingly used to safely and effectively correct iron deficiency anemia, but some formulations are linked to a renal phosphate wasting syndrome which is mediated by fibroblast growth factor 23. Unawareness among prescribers and the nonspecific clinical symptoms of hypophosphatemia result in underreporting of this complication. Even though it is often an asymptomatic and self-limiting condition, accumulating evidence from case reports and dedicated randomized controlled trials show that IV iron induced hypophosphatemia may be associated with clinical symptoms.